MarginsXMarginsX
Home › Markets › Health Care › IDXX

IDEXX Laboratories Inc. (IDXX)

IDXX trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$700.65
-0.51% on the day
Market cap
$55.2B
Large cap
Revenue · 2025
$4.3B
+10.4% on 2024
Net income · 2025
$1.1B
24.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000038/0000874716-26-000038-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIDXX on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year1991
SEC CIK0000874716
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$4.3B
Net income$1.1B
Operating income$1.4B
Net margin24.6%
Operating margin31.6%
Revenue growth+10.4%
Cash$180.1M
Total assets$3.4B
P/E (computed)52.1×
P/S (computed)12.8×

Warning signs

Cash runway
Cash-flow positive
$197.5M cash at September 30, 2026
Share count, 1 year
-1.3%
2025-10-29 to 2026-10-28 · -5.1% over 3 years
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$37.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$197.5M cash; operating cash flow $354.7M a quarter.Report 2026-09-30
Shares outstanding78,786,265 (2026-10-28); 79,851,330 a year earlier; 83,051,702 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $37.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.2B$317.1M$449.7M$197.5M$374.9M$4.7B10-Q 2026-11-02
Q2 2026
2026-06-30
$1.2B$338.4M$347.2M$196.9M$449.9M$4.6B10-Q 2026-08-04
Q1 2026
2026-03-31
$1.1B$278.4M$266.2M$200.5M$449.9M$4.4B10-Q 2026-05-05
Q4 2025
2025-12-31
$1.1B$248.2M$355.8M$180.1M$450.0M$4.3B10-K 2026-02-20
Q3 2025
2025-09-30
$1.1B$274.6M$402.3M$208.2M$524.8M$4.2B10-Q 2026-11-02
Q2 2025
2025-06-30
$1.1B$294.0M$185.7M$164.6M$524.8M$4.0B10-Q 2026-08-04
Q1 2025
2025-03-31
$998.4M$242.7M$238.0M$164.0M$620.7M$3.9B10-Q 2026-05-05
Q4 2024
2024-12-31
$954.3M$216.1M$262.0M$288.3M$617.8M$3.9B10-K 2026-02-20

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-20
Latest quarterly / interim10-Q2026-11-02
Latest current report
FORM 8-K
8-K2026-11-02
Latest proxyDEFA14A2026-03-27

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.2%
1 month+35.3%
3 months+24.2%
Year to date+4.1%
1 year+0.4%
From 52-week high-8.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
ORKAOruka Therapeutics Inc.$99.24-5.80%$6.7B
LNTHLantheus Holdings Inc.$101.72+0.13%$6.7B
NEOGNeogen Corporation$10.88-3.12%$2.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier